Oral therapy for erectile dysfunction: An overview

Main Article Content

M Soni
K Patidar
D Sharma1
P Soni2
D K Sharma2


Over the past 20 years, treat ment options for erectile dysfunction (ED) have become more effective and, despite the effectiveness of intracavernous injections, vacuum devices, surgery and other treatments, there has been a trend toward
the development of less-invasive modalities. Oral drugs have become the first-line therapeutic option for many men with ED. This review highlights the pathophysiology of ED, oral therapy for ED and new drug targets for the treatment of ED
products available in the market for ED.


Download data is not yet available.

Article Details

How to Cite
Soni, M., Patidar, K., Sharma1, D., Soni2, P., & Sharma2, D. K. (2014). Oral therapy for erectile dysfunction: An overview. Asian Journal of Pharmaceutics (AJP), 3(3). https://doi.org/10.22377/ajp.v3i3.262


NIH Consensus Conference. Impotence NIH Consensus Development

Panel on Impotence. JAMA 1993;270:83-90.

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB.

Impotence and its medical and psychosocial correlates: Results of the

Massachusetts Male Aging Study. J Urol 1994;151:54-61.

Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States:

Prevalence and predictors. JAMA 1999;281:537-44.

Aytac IA, McKinley JB, Krane RJ. The likely worldwide increase in

erectile dysfunction between 1995 and 2025 and some possible policy

consequences. BJU Int 1999;84:50-6.

de Tejada SI, Blanco R, Goldstein I, Azadzoi K, De Las Morenas A,

Krane RJ, et al. Cholinergic neurotransmission in human corpus

cavernosum. I. Responses of isolated tissue. Am J Physiol 1988;25:459-67.

Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric

oxide and cyclic GMP formation upon electrical field stimulation cause

relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res

Commun 1990;170:843-50.

Lerner SE, Melman A, Christ GJ. A review of erectile dysfunction: New

insights and more questions. J Urol 1993;149:1246-55.

Melman A, Gingell JC. The epidemiology and pathophysiology of erectile

dysfunction. J Urol 1999;161:5-11.

Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The

relationship between depressive symptoms and male erectile

dysfunction: Cross-sectional results from the Massachusetts Male Aging

Study. Psychosom Med 1998;60:458-65.

Cooke JP. Therapeutic interventions in endothelial dysfunction:

endothelium as a target organ. Clin Cardiol 1997;2:45-51.

Pfizer Inc. Viagra (sildenafil citrate) tablets: Prescribing information.

Pfizer Inc; 2000.

Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro

and on the activities of cyclic nucleotide phosphodiesterase isozymes.

J Urol 1998;159:2164-71.

Dinsmore WW, Hodges M, Hargreaves C, Osterloh IH, Smith MD, Rosen Rc.

Sildenafil citrate (Viagra) in erectile dysfunction: Near normalization

in men with broad-spectrum erectile dysfunction compared with

age- atched healthy control subjects. J Urol 1999;53:800-5.

mRendell MS, Rajfer J, Wicker PA, Smith MD for the Sildenafil Diabetes

Study Group. Sildenafil for treatment of erectile dysfunction in men

with diabetes: A randomized controlled trial JAMA 1999;281:421-6.

Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update

of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract


Olsson AM, Persson CA. Efficacy and safety of sildenafil citrate for the

treatment of erectile dysfunction in men with cardiovascular disease.

Int J Clin Pract 2001;55:171-6.

Zesiewicz TA, Hauser RA, Helal M. Sildenafil citrate (Viagra) for the

treatment of erectile dysfunction in men with Parkinson’s disease.

Neurology 1999;52:305-8.

Palmer JS, Kaplan WE, Firlit CF. Erectile dysfunction in patients with

spina bifida is a treatable condition. J Urol 2000;164:958-61.

Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety

of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction.

Int J Impot Res 1998;10:69-74.

Heaton JP. Key issues from the clinical trials of apomorphine SL. World

J Urol 2001;19:25-31.

Mulhall JP, Bukofzer S, Edmonds AL, George M; Apomorphine SL

Study Group. An open-label, uncontrolled dose-optimization

study of sublingual apomorphine in erectile dysfunction. Clin Ther


Morales A. Yohimbine in erectile dysfunction: The facts. Int J Impot Res


Porst H. IC351 (tadalafil, Cialis): Update on clinical experience. Int

J Impot Res 2002;14:57-64.

Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E,

et al. The efficacy and tolerability of vardenafil, a new, oral, selective

phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction:

The first at-home clinical trial. Int J Impot Res 2001;13:192-9.

Chitaley K, Webb RC, Mills TM. RhoA/Rho-kinase: A novel player in the

regulation of penile erection. Int J Impot Res 2001;13:67-72.

Sullivan ME, Dashwood MR, Thompson CS, Muddle JR, Mikhailidis DP,

Morgan RJ. Alterations in endothelin B receptor sites in cavernosal

tissue of diabetic rabbits: Potential relevance to the pathogenesis of

erectile dysfunction. J Urol 1997;158:1966-72.

Available from: http://www.natural-cure-guide.com

Available from: www.altmedicine zone.com